The stock of OvaScience Inc (NASDAQ:OVAS) is a huge mover today! About 1.02 million shares traded hands or 160.47% up from the average. OvaScience Inc (NASDAQ:OVAS) has declined 50.74% since April 4, 2016 and is downtrending. It has underperformed by 51.83% the S&P500.
The move comes after 7 months negative chart setup for the $136.18 million company. It was reported on Nov, 4 by Barchart.com. We have $3.32 PT which if reached, will make NASDAQ:OVAS worth $19.07 million less.
OvaScience Inc (NASDAQ:OVAS) Ratings Coverage
Out of 5 analysts covering OvaScience (NASDAQ:OVAS), 1 rate it a “Buy”, 1 “Sell”, while 3 “Hold”. This means 20% are positive. OvaScience has been the topic of 9 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The rating was downgraded by Oppenheimer on Monday, January 25 to “Perform”. The rating was downgraded by Leerink Swann to “Market Perform” on Monday, November 9. On Tuesday, September 29 the stock rating was downgraded by JMP Securities to “Mkt Perform”. The stock has “Outperform” rating given by Wedbush on Tuesday, August 11. The firm has “Outperform” rating given on Friday, August 14 by Leerink Swann. The firm earned “Outperform” rating on Wednesday, September 30 by Oppenheimer. On Thursday, January 21 the stock rating was initiated by Credit Suisse with “Underperform”. Oppenheimer maintained it with “Outperform” rating and $16 target price in Wednesday, October 21 report.
According to Zacks Investment Research, “OvaScience, Inc. is a life science company focused on the discovery, development and commercialization of new treatments for infertility. Its product includes Augment for the treatment of infertility and Ova Ture used in the creation of mature fertilizable eggs. Ova Science, Inc. is headquartered in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 3.37 in 2016 Q2. Its up 2.50, from 0.87 in 2016Q1. The ratio is positive, as 7 funds sold all OvaScience Inc shares owned while 12 reduced positions. 17 funds bought stakes while 47 increased positions. They now own 51.93 million shares or 132.78% more from 22.31 million shares in 2016Q1.
Portolan Capital Management Ltd last reported 0.3% of its portfolio in the stock. The New York-based Millennium Management Ltd Liability has invested 0% in OvaScience Inc (NASDAQ:OVAS). Amici Capital Ltd holds 0.01% of its portfolio in OvaScience Inc (NASDAQ:OVAS) for 10,000 shares. Moreover, Retail Bank Of Montreal Can has 0% invested in OvaScience Inc (NASDAQ:OVAS) for 908 shares. D E Shaw holds 0% of its portfolio in OvaScience Inc (NASDAQ:OVAS) for 45,254 shares. Credit Suisse Ag holds 0% of its portfolio in OvaScience Inc (NASDAQ:OVAS) for 26,312 shares. Mount Lucas Mgmt Lp holds 0% or 3,300 shares in its portfolio. Quantitative Systematic Strategies Ltd Liability Company last reported 30,504 shares in the company. Blackrock Gru, a United Kingdom-based fund reported 22,600 shares. Panagora Asset Mngmt, a Massachusetts-based fund reported 915 shares. Fny Managed Accounts Llc reported 40,000 shares or 0% of all its holdings. The Delaware-based Blackrock Advsrs Ltd has invested 0% in OvaScience Inc (NASDAQ:OVAS). Alliancebernstein Limited Partnership holds 0% of its portfolio in OvaScience Inc (NASDAQ:OVAS) for 55,400 shares. Manufacturers Life Co The holds 0% or 23,773 shares in its portfolio. Deutsche Commercial Bank Ag has 14,084 shares for 0% of their US portfolio.
Insider Transactions: Since May 10, 2016, the stock had 10 insider purchases, and 0 selling transactions for $1.76 million net activity. $250,395 worth of OvaScience Inc (NASDAQ:OVAS) shares were bought by Dipp Michelle. 20,000 shares were bought by ALDRICH RICHARD, worth $157,200. $22,847 worth of shares were bought by CHAPMAN PAUL W.D. on Tuesday, May 10.
OVAS Company Profile
OvaScience, Inc., incorporated on April 5, 2011, is a global fertility company. The Firm is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is specifically designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization (IVF) process to supplement the existing mitochondria.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.